Benzinga | Jan 18, 2022 07:06AM EST

Alkermes To Present Data On Nemvaleukin Alfa At American Society Of Clinical Oncology Gastrointestinal Cancers Symposium Jan. 20

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 1/2 study evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA(r)), and preclinical data from the study of nemvaleukin in combination with novel agents in GI cancers.

Details of the presentation are as follows:

Abstract: 659

Title: Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: preclinical evidence and clinical data from the ARTISTRY-1 trial

Presenter: Ulka N. Vaishampayan, M.D., Professor, Internal Medicine, Division of Hematology/Oncology, University of Michigan

Presentation Date: The poster, along with a pre-recorded presentation, will be available on the ASCO GI virtual meeting platform beginning Jan. 20, 2022.